Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$4.20
-3.9%
$3.24
$2.12
$5.80
$434.06M1.971.50 million shs2.51 million shs
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
$4.26
$4.23
$2.06
$4.50
$370.71M1.181.54 million shsN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
$7.19
-3.2%
$6.84
$4.58
$9.78
$372.52M1.89476,422 shs405,537 shs
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
$0.63
+1.4%
$0.66
$0.33
$0.80
$86.38M-0.14123,508 shs42,766 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
+8.44%+8.44%+30.45%+74.10%+40.97%
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
0.00%0.00%0.00%+5.45%+59.55%
CryoPort, Inc. stock logo
CYRX
CryoPort
-0.27%-1.07%+10.24%+33.87%-12.28%
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
+6.90%-9.95%+3.32%+38.08%-12.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
1.5572 of 5 stars
3.53.00.00.01.40.00.0
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
0.4751 of 5 stars
1.20.00.04.21.80.00.0
CryoPort, Inc. stock logo
CYRX
CryoPort
2.4035 of 5 stars
3.41.00.00.02.92.50.6
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
2.1978 of 5 stars
3.55.00.00.00.01.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
3.00
Buy$10.14141.50% Upside
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
2.33
Hold$4.331.72% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.75
Moderate Buy$10.8851.25% Upside
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
3.00
Buy$1.50138.51% Upside

Current Analyst Ratings Breakdown

Latest XTNT, CKPT, AQST, and CYRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/7/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $10.00
6/17/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
6/2/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$7.00
5/15/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/8/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/5/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$57.56M7.25N/AN/A($0.66) per share-6.36
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
$41K9,041.59N/AN/A($0.47) per share-9.06
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.58N/AN/A$7.44 per share0.97
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
$117.27M0.75N/AN/A$0.31 per share2.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$44.14M-$0.59N/AN/AN/A-100.02%N/A-50.31%8/5/2025 (Estimated)
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$51.85M-$1.29N/AN/AN/AN/A-659.07%8/11/2025 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M-$2.34N/AN/AN/A-50.15%-11.03%-5.54%8/5/2025 (Estimated)
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
-$16.45M-$0.13N/AN/A-9.81%-27.01%-12.49%8/14/2025 (Estimated)

Latest XTNT, CKPT, AQST, and CYRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$0.02N/AN/AN/A$7.28 millionN/A
8/5/2025Q2 2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.18N/AN/AN/A$11.32 millionN/A
8/5/2025Q2 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20N/AN/AN/A$41.74 millionN/A
5/13/2025Q1 2025
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$0.10-$0.19-$0.09-$0.19$4.53 millionN/A
5/12/2025Q1 2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.17-$0.24-$0.07-$0.24$12.23 million$8.72 million
5/7/2025Q1 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/AN/AN/AN/AN/A
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/A
4.87
4.48
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
N/A
0.29
0.29
CryoPort, Inc. stock logo
CYRX
CryoPort
0.51
5.56
5.24
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
0.51
2.34
1.03

Institutional Ownership

CompanyInstitutional Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
32.45%
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
22.00%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
69.33%

Insider Ownership

CompanyInsider Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
8.35%
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
2.10%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
9.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
16099.33 million91.03 millionOptionable
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
1087.02 million47.81 millionOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.14 million45.12 millionOptionable
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
120139.32 million125.81 millionNot Optionable

Recent News About These Companies

6XTNT : A Glimpse of Xtant Medical Hldgs&#...
Xtant Medical sees Q1 revenue $32.8M-$33.1M, two estimates $30.65M

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aquestive Therapeutics stock logo

Aquestive Therapeutics NASDAQ:AQST

$4.20 -0.17 (-3.89%)
Closing price 04:00 PM Eastern
Extended Trading
$4.24 +0.04 (+0.95%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Checkpoint Therapeutics stock logo

Checkpoint Therapeutics NASDAQ:CKPT

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$7.19 -0.24 (-3.23%)
Closing price 04:00 PM Eastern
Extended Trading
$7.29 +0.10 (+1.39%)
As of 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Xtant Medical stock logo

Xtant Medical NYSEAMERICAN:XTNT

$0.63 +0.01 (+1.44%)
As of 04:10 PM Eastern

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana.